TORONTO, Canada -- November 5, 2020 -- InvestorsHub NewsWire --
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX
Venture: ARCH and OTCQB:
ACHFF), announced today that patient dosing in Turkey has begun
in the Phase II trial of its lead drug LSALT peptide, targeting
prevention of acute lung injury, acute kidney injury and other
complications caused by inflammation in hospitalized patients with
moderate to severe cases of COVID-19.
The first patient was dosed in Istanbul yesterday and patient
recruitment at the Istanbul site is now ongoing. Additional
patients are expected to be enrolled this week at a second clinical
site in Ankara, the nation’s capital.
In recent weeks, COVID-19 infection rates in Turkey have
worsened to over 2,000 official cases per day, up from an average
of approximately 900 daily cases in July. Since the second
wave of Covid-19 infection emerged in Turkey in late summer, new
COVID-19 hospitalizations continue to strain the Turkish medical
system and there have been over 10,000 deaths so far in
2020.
The Phase II trial continues to recruit patients in two hospital
sites in the U.S. (in Florida and Louisiana) while the Company is
exploring the opportunity to add Canadian clinical sites to the
trial.
About the Phase II trial for LSALT Peptide
The Phase II trial is an international, multicenter, randomized,
double-blind, placebo-controlled, proof of concept study of LSALT
peptide (Metablok) as prevention of organ inflammation known to
trigger acute respiratory distress syndrome (ARDS) and acute kidney
injury (AKI) in patients infected with SARS-CoV-2 (COVID-19).
Patient enrollment is initially planned to be 60 patients.
The composite primary endpoint of the phase II trial reflects
the severe effects often experienced by hospitalized COVID-19
patients and deemed appropriate for LSALT peptide’s novel mechanism
of action in blocking consequential inflammation in the lungs and
kidneys.
The Phase II results will be used to design the Phase III trial,
including greater patient numbers to more fully evaluate efficacy
and safety in COVID patients.
About COVID-19
COVID-19 is the disease caused by the novel coronavirus
SARS-CoV-2 that emerged in China in late 2019. Severe complications
from COVID-19 are in large part due to excessive host immune
responses to the virus that result in progressive lung inflammation
and acute respiratory distress syndrome that often requires
mechanical ventilation and critical care1. Patients with severe
COVID-19 also experience multiple organ dysfunction including acute
kidney injury, liver dysfunction, cardiac failure, and blood
abnormalities. Currently, no approved vaccine or effective
antiviral drug exists for SARS-CoV-2. Treatment of severe COVID-19
has been primarily supportive, relying heavily on respiratory,
infectious disease and critical care medicine.
Survival rates and health care system capacity could both be
improved with new treatments that prevent the severe manifestations
of COVID-19, such as worsening lung inflammation (ARDS) and AKI
experienced by patients infected with SARS-CoV-2.
1 J. S. Ayres, Sci.
Adv 10.1126/sciadv.abc1518 (2020)
About Arch Biopartners
Arch Biopartners Inc. is a clinical stage company focused on the
development of innovative technologies that have the potential to
make a significant medical or commercial impact. Arch is
developing a pipeline of new drug candidates that inhibit
inflammation in the lungs, liver and kidneys via the dipeptidase-1
(DPEP-1) pathway for multiple medical indications.
For more information on Arch Biopartners, its technologies and
other public documents Arch has filed on SEDAR, please visit
www.archbiopartners.com
The Company has 60,782,302 common shares outstanding.
Forward-Looking Statements
All statements, other than statements of historical fact, in
this news release are forward looking statements that involve
various risks and uncertainties, including, without limitation,
statements regarding the future plans and objectives of the
Company. There can be no assurance that such statements will prove
to be accurate. Actual results and future events could differ
materially from those anticipated in such statements. These and all
subsequent written and oral forward-looking statements are based on
the estimates and opinions of management on the dates they are made
and are expressly qualified in their entirety by this notice. The
Company assumes no obligation to update forward-looking statements
should circumstances or management’s estimates or opinions
change.
The science and medical contents of this release have been
approved by the Company’s Chief Science Officer
The Company is not making any express or implied claims that
its product has the ability to eliminate, cure or contain Covid-19
(or SARS-2 Coronavirus) at this time
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
For more information, please contact:
Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
ARch Biopartners (QB) (USOTC:ACHFF)
Historical Stock Chart
From Nov 2024 to Dec 2024
ARch Biopartners (QB) (USOTC:ACHFF)
Historical Stock Chart
From Dec 2023 to Dec 2024
